Botox 200 unit vials
Ended Awarded Last action
- Contract number
- SPE2DR26FJUV2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $39,610
Award facts
- Contract value 100% obligated
- $39,609.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $39,609.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of BOTOX 200 Unit Vials. The delivery order, issued on December 11, 2025, with an ultimate completion date of January 5, 2026, carries no set-aside designation, indicating the award was made through open competition. DMS Pharmaceutical Group will perform all work at its facility in Park Ridge, Illinois. This delivery order is issued under the company's single-award Indefinite Delivery Contract (IDC) designated SPE2DR under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to support recurring pharmaceutical supply needs across the Department of Defense's global medical infrastructure.
PPV-G GEN V authorizes the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, vaccines, and medical consumables. DMS Pharmaceutical Group's IDC, awarded November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, structured with a 30-month base period and three 30-month option periods. The vendor has demonstrated substantial federal contracting capability through consistent performance on numerous prior delivery orders across multiple therapeutic categories, positioning it as a critical supplier within the Department of Defense's pharmaceutical supply chain. No subcontractors are identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FJUV2?
SPE2DR26FJUV2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 11, 2025.
How much is contract SPE2DR26FJUV2 worth?
The government has obligated $39,610 on SPE2DR26FJUV2.
Is contract SPE2DR26FJUV2 an order under another contract?
Yes. SPE2DR26FJUV2 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUV2 competed?
The extent of competition for SPE2DR26FJUV2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award